-
Nov 20, 2020
F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals -
Nov 11, 2020
F-star Therapeutics to Present New Clinical and Mechanistic Data on its LAG-3/PD-L1 Tetravalent Bispecific Antibody, FS118, at the SITC 2020 Virtual Annual Meeting -
Oct 22, 2020
F-star Therapeutics to Present at SITC 2020 Virtual Annual Meeting -
Sep 09, 2020
F-star Therapeutics to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference -
Aug 05, 2020
F-star Therapeutics to Participate in BTIG Virtual Biotechnology Conference -
Jul 30, 2020
Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies -
Jul 16, 2020
Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration -
Jun 22, 2020
F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting -
Apr 28, 2020
F-star Therapeutics Announces Positive Preclinical Antitumor Activity and Safety of FS222 Published in Clinical Cancer Research -
Apr 16, 2020
A Novel Mechanism of Action for FS118 and the Potential to Overcome PD-(L)1 Resistance Published in Clinical Cancer Research
Pagination
